Last reviewed · How we verify

NCT06596863

Serum Uromodulin and DN Systematic Review and Meta Analysis

Completed Last updated 19 September 2024
What this trial tests

trial testing The association of serum uromodulin with DN in Diabetic Nephropathies in 1,774 participants. Completed in 30 May 2024.

Timeline
1 May 2024
Primary endpoint
30 May 2024
30 May 2024

Quick facts

Lead sponsorTanta University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,774
Start date1 May 2024
Primary completion30 May 2024
Estimated completion30 May 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Eligibility, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several studies have investigated the association between the changes of serum uromodulin and diabetic nephropathy (DN). However, the results are still controversial. Hence, this meta-analysis aimed to evaluate the association of uromodulin with DN.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Association of serum uromodulin with diabetic kidney disease: a systematic review and meta-analysis.
    Barr SI, Abd El-Azeem EM, Bessa SS, Mohamed TM. · · 2024 · cited 3× · PMID 39581971 · DOI 10.1186/s12882-024-03854-x

Verify or expand the search:

Other recruiting trials for Diabetic Nephropathies

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06596863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing